HILLSIDE, N.J., June 28 /PRNewswire-FirstCall/ -- AgroLabs, Inc., a wholly-owned subsidiary of Integrated BioPharma, Inc. (Amex: INB), announced today that it began shipments of its proprietary Naturally Noni(TM) and Naturally Pomegranate(TM) products to more than 5,250 Walgreen Co. drugstores nationwide.
Kurt E. Cahill, Chief Operating Officer of AgroLabs, stated "We continue to gain distribution throughout the food, drug and mass merchandising channels, which is in line with our strategic efforts."
E. Gerald Kay, Chief Executive Officer of INB, added, "The addition of more than 5,000 Walgreens stores as another distribution channel significantly helps us to make our products widely available in various sizes and forms."
Walgreen Co. was founded in 1901 and is the nation's largest drugstore chain with fiscal 2005 sales of $42.2 billion. The company operates 5,251 stores in 45 states and Puerto Rico. The company expects to open about 475 stores in fiscal 2006 for a total of 390 net new stores.
AgroLabs, Inc. distributes and markets healthful nutritional products under the following brands: Naturally Aloe(TM), Naturally Noni(TM), Naturally Pomegranate(TM), Naturally Thai Mangosteen(TM) and most recently, Acai Extreme Energy(TM). These products are distributed nationwide through major mass market, grocery, drug and vitamin retailers. Additional information on AgroLabs and its products can be obtained from its website at www.agrolabs.com or by calling .
About Integrated BioPharma Inc. (INB)
Integrated BioPharma is a unique grouping of companies presently serving the varied needs of the health care industry. Through its nutraceutical business, the Company creates, develops, manufactures and markets products worldwide. The Company's biotechnology business uses its patented plant-based technology to produce vaccines and therapeutic antibodies. Its pharmaceutical business operates a cGMP facility for the production and sale of Paclitaxel and related drugs and provides technical services through its contract research organization. Further information is available at www.iBioPharma.com
Statements included in this release related to Integrated BioPharma, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential risk factors that could affect the Company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.
SOURCE Integrated BioPharma, Inc.